Longitudinal monitoring of sex-related in vivo metabolic changes in the brain of Alzheimer's disease transgenic mouse using magnetic resonance spectroscopy

Journal of Alzheimer's Disease

Volumn 34, Issue 4, 2013, Pages 1051-1059

  Van Duijn, Sara ^a   Nabuurs, Rob J A ^a   Van Duinen, Sjoerd G ^a   Natté, Remco ^a   Van Buchem, Mark A ^a   Alia, A ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; A PP PS1 transgenic mouse model; longitudinal studies; magnetic resonance spectroscopy; sex differences

Indexed keywords

GLUTAMIC ACID; INOSITOL; N ACETYLASPARTIC ACID; TAURINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LONGITUDINAL STUDY; MALE; MOUSE; NEUTRON ACTIVATION ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SEX DIFFERENCE; TRANSGENIC MOUSE;

EID: 84876379152     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122188     Document Type: Article

References (33)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
2. Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12, 295-312.
3. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
4. Fox NC, Freeborough PA, Rossor MN (1996) Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 348, 94-97. (Pubitemid 26234357)
5. Musicco M (2009) Gender differences in the occurrence of Alzheimer's disease. Funct Neurol 24, 89-92.
6. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A (1999) Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53, 1992-1997.
7. Janicki SC, Schupf N (2010) Hormonal influences on cognition and risk for Alzheimer's disease. Curr Neurol Neurosci Rep 10, 359-366.
8. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R (2011) Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 32, 802-810.
9. Lalonde R, Kim HD, Maxwell JA, Fukuchi K (2005) Exploratory activity and spatial learning in 12-monthold APP(695)SWE/co + PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett 390, 87-92. (Pubitemid 41415812)
10. Bereczki E, Bernat G, Csont T, Ferdinandy P, Scheich H, Santha M (2008) Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J Proteome Res 7, 2246-2252.
11. Chen SQ,Wang PJ, Ten GJ, ZhanW, Li MH, Zang FC (2009) Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord 28, 558-566.
12. Connor DM, Benveniste H, Dilmanian FA, KritzerMF, Miller LM, Zhong Z (2009) Computed tomography of amyloid plaques in a mouse model of Alzheimer's disease using diffraction enhanced imaging. Neuroimage 46, 908-914.
13. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van GT, Broersen LM, Lutjohann D, Heerschap A, Tanila H, Kiliaan AJ (2007) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 28, 16-29. (Pubitemid 47432903)
14. Manaye KF, Wang PC, O'Neil JN, Huang SY, Xu T, Lei DL, Tizabi Y, Ottinger MA, Ingram DK, Mouton PR (2007) Neuropathological quantification of dtg APP/PS1: Neuroimaging, stereology, and biochemistry. Age 29, 87-96. (Pubitemid 350112202)
15. Ruan L, Kang Z, Pei G, Le Y (2009) Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res 6, 531-540.
16. Xu W, Zhan YQ, Huang W, Wang XX, Zhang SM, Lei H (2010) Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons. J Neurosci Res 88, 3155-3160.
17. Wang J, Tanila H, Puolivali J, Kadish I, vanGT (2003) Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 14, 318-327. (Pubitemid 37543511)
18. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC (2001) Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 158, 1173-1177. (Pubitemid 32221809)
19. Westman E, Spenger C, Oberg J, Reyer H, Pahnke J,Wahlund LO (2009) In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neurosci 10, 33.
20. Choi JK, Jenkins BG, Carreras I, Kaymakcalan S, Cormier K, KowallNW, DedeogluA(2010) Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol 223, 377-384.
21. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG (2004) Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012, 60-65. (Pubitemid 38648899)
22. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR Jr, Ugurbil K, Garwood M (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 102, 11906-11910. (Pubitemid 41170823)
23. Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, Sunnemark D, Norinder U, Klason T, Wahlund LO, Lindberg M (2008) Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 29, 1423-1433. (Pubitemid 351970599)
24. von Kienlin M, Kunnecke B, Metzger F, Steiner G, Richards JG, Ozmen L, Jacobsen H, Loetscher H (2005) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18, 32-39. (Pubitemid 40092895)
25. Braakman N, Oerther T, de Groot HJ, Alia A (2008) High resolution localized two-dimensionalMRspectroscopy in mouse brain in vivo. Magn Reson Med 60, 449-456.
26. Gruetter R (1993) Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med 29, 804-811. (Pubitemid 23182863)
27. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508, 333-348.
28. Mandal PK (2007) Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease. Conc Magn Reson A 30A, 40-64.
29. Tkac I, Starcuk Z, Choi IY, GruetterR(1999) In vivo 1HNMR spectroscopy of rat brain at 1ms echo time. Magn Reson Med 41, 649-656. (Pubitemid 29205710)
30. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo protonNMRspectra. Magn Reson Med 30, 672-679. (Pubitemid 23360802)
31. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868. (Pubitemid 27408156)
32. Taniuchi N, Niidome T, Goto Y, Akaike A, Kihara T, Sugimoto H (2007) Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. Neuroreport 18, 1801-1805. (Pubitemid 350303755)
33. Wilkinson ID, Paley MN, Miszkiel KA, Hall-Craggs MA, Kendall BE, Chinn RJ, Harrison MJ (1997) Cerebral volumes and spectroscopic proton metabolites on MR: Is sex important? Magn Reson Imaging 15, 243-248. (Pubitemid 27173237)